TORONTO, ONTARIO--(Marketwired - April 10, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) is pleased to announce that it has today filed a prospectus supplement (the "Prospectus") to the Company's short form base shelf prospectus dated October 15, 2012, regarding its previously announced public offering of units of the Company ("Units"). Each Unit consists of one common share ("Share") of the Company and one Share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to acquire one Share at a price of $2.75 for a period of 36 months following the Closing Date (as defined below).
Dundee Securities Ltd. (the "Agent") has agreed to sell, on a best efforts agency basis and, pursuant to the terms and conditions of an agency agreement dated April 10, 2014 between the Company and the Agent (the "Agency Agreement"), 10,611,469 Units at a price of $2.10 per Unit (the "Offering") for total gross proceeds of $22,284,085. The Agent has been granted the option to offer for sale up to an additional 15% of the Units issued under the Offering, exercisable in whole or in part on the Closing Date or at any time up to 30 days following the Closing Date. BayFront Capital Partners Ltd. is acting as a selling group member in connection with the Offering.
The Offering is scheduled to close on or about April 23, 2014 (the "Closing Date"). The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals.
The Securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
For further details regarding the Offering, please see the Company's press release dated April 7, 2014, the Prospectus and the Agency Agreement, copies of which are available under the Company's profile at www.sedar.com.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's Single Port Orifice Robotic Technology, SPORT™ Surgical System, currently under development, comprises a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures. The SPORT™ Surgical System is being designed to expand robotic surgery into areas of surgical specialties and simple and complex procedures that are currently under-serviced, and to allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. For more information, visit the Company's website at www.titanmedicalinc.com.
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 4, 2014 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.